• 1
    Beaumont JL, Butt Z, Baladi J, et al. Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist. 2011; 16: 632-640.
  • 2
    Cella D, Michaelson MD, Bushmakin AG, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010; 102: 658-664.
  • 3
    Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006; 4: 191-199.
  • 4
    Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007; 10: 285-293.
  • 5
    Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003; 21: 526-535.
  • 6
    Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002; 83(12 suppl 2): S10-S17.
  • 7
    US Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: US Food and Drug Administration; 2009. 071975.pdf. Accessed November 26, 2011.
  • 8
    Rao D, Butt Z, Rosenbloom S, et al. A comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage. 2009; 38: 291-298.
  • 9
    McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31: 247-263.
  • 10
    Cella D, Beaumont JL, Liu Z, Phan AT, Choi S, Yao JC. Neuroendocrine tumor disease state and PROMIS health-related quality of life scores [abstract]. J Clin Oncol. 2010; 28: 15s.
  • 11
    Liu H, Cella D, Gershon R, et al. Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol. 2010; 63: 1169-1178.
  • 12
    Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoecon Outcomes Res. 2004; 4: 515-523.
  • 13
    Cella D, Escudier B, Rini BI, et al. Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as a second-line therapy for metastatic renal cell carcinoma (mRCC). Proceedings of the 2011 ASCO Annual Meeting. J Clin Oncol. 2011; 29(15 suppl): abstract 4504.